ArticleCardiovascular diabetology2025
Comparison of biological properties of human adipose tissue-derived mesenchymal stem/ stromal cells from healthy and diabetic donors: consequences for cell-based medicinal product development.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is a civilisation disease that can cause damage to tissues and organs as well as affects the biological properties of cells isolated from these tissues. In recent years, there has been increasing interest in cell-based therapies, including the use of mesenchymal stem/stromal cells (MSCs). Therefore, the aim of the current study was to compare the biological potential of adipose tissue-derived MSCs (AT-MSCs) from healthy and diabetic donors under in vitro conditions and to clarify the implications for cell-based medicinal product development. Biological potential of both populations of AT-MSCs was also investigated in the relation to their major therapeutic mechanisms of action-we focused on the chondrogenic and osteogenic differentiation capacity of AT-MSCs and their pro-angiogenic potential.
methodsHuman AT-MSCs derived from healthy and type 2 diabetes (T2D) donors underwent biological characterization including assessment of: morphology, viability, antigenic profile, proliferation, presence of senescent cells and oxidative stress, pro-angiogenic properties of AT-MSC secretome as well as trilineage differentiation potential in vitro. AT-MSCs were cultured under the control and diabetes mimicking culture conditions.
resultsWe observed no significant differences in morphology, viability, expression of MSC markers, proliferation rate, concentration of oxidative stress marker (8OHdG) and content of senescent cells between AT-MSCs from healthy and T2D donors under control culture conditions. The conditioned medium from a culture of diabetic AT-MSCs was found to improve the pro-angiogenic potential of human umbilical vein endothelial cells (HUVECs), compared with the medium from healthy AT-MSCs. HUVECs that were incubated in conditioned media collected from healthy AT-MSCs from diabetic culture conditions, exhibited greater potential to form capillary-like structures. Furthermore, diabetic culture conditions induced the oxidative stress in healthy AT-MSCs. Diabetic AT-MSCs exhibited greater chondrogenic differentiation capacity along with lower adipogenic differentiation potential and comparable osteogenic differentiation capacity when compared to healthy donor-derived AT-MSCs.
conclusionsThe present study provides evidence of the biological potential of AT-MSCs from diabetic donors, which can be used as an active substance in the development of cell-based autologous advanced therapy medicinal products (ATMPs) dedicated for the treatment of e.g. osteoarthritis or myocardial infarction. Diabetic AT-MSCs in the used culture conditions are functional cells with greater chondrogenic and pro-angiogenic potential when compared to AT-MSCs from healthy donors. This increases the possibility of treating diabetic patients using their own cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.